Kelun-Biotech to present sac-TMT, lunbotinib fumarate studies at ASCO

Kelun-Biotech reported that its TROP2-directed ADC sacituzumab tirumotecan combined with pembrolizumab showed a statistically significant and clinically meaningful improvement in progression-free survival versus pembrolizumab alone in first-line PD-L1-positive metastatic NSCLC, alongside a markedly higher response rate, with results selected for oral presentation at ASCO. next-generation RET inhibitor lunbotinib showed high clinical activity in a pivotal Phase II study of RET-fusion positive NSCLC, with ORR of 87.1% in pre-treated and 81.3% in treatment-naive patients, long median PFS, and durable survival signals with 24-month OS rates up to 74.1%, supporting strong efficacy in both treatment settings.